Your AI-Trained Oncology Knowledge Connection!

News

Video

Comparing Treatment Combinations in Renal Cell Carcinoma

Author(s):

Ulka Vaishampayan, MD,Alan Tan, MD

A comprehensive discussion on VEGF-TKI-based combinations and immune checkpoint inhibitor combinations in the treatment of renal cell carcinoma, featuring key clinical trial results and treatment strategies.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Bradley McGregor, MD
Sairah Ahmed, M.D
Regina Barragan-Carrillo, MD
4 experts are featured in this series.
Brandon G. Smaglo, MD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Kathryn E. Beckermann, MD, PhD
Related Content
Image Credit: Sebastian Kaulitzki – stock.adobe.com
March 21st 2025

First-Line Atezolizumab Is Suitable in Platinum-Based Chemotherapy Ineligible mUC

Ibrahim T. Aldoss, MD, associate professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
March 20th 2025

Ponatinib Monotherapy Maintains MRD Negativity Following TKI/Chemotherapy Treatment in Ph+ ALL: With Ibrahim T. Aldoss, MD; and Elias Jabbour, MD

RCC | Image Credit: © Crystal light – stock.adobe.com
March 19th 2025

Fruquintinib/Sintilimab Generates Favorable PFS Outcomes in Advanced RCC

Oncology Unplugged With Dr Chandler Park
February 26th 2025

Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD

Casdatifan in ccRCC | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 12th 2025

Casdatifan Monotherapy Shows Early Efficacy Signals and Tolerable Safety Profile in Pretreated ccRCC

MT-8421 in Advanced Solid Tumors | Image Credit: © Cornflakesei – stock.adobe.com
March 11th 2025

MT-8421 Displays Acceptable Safety Profile in First-in-Human Trial for Advanced Solid Tumors